CD44 and melanoma: Through receptors such as CD44 and RHAMM, HA activates signalling pathways including MAPK/ERK that support melanoma cell survival and motility, and elevated HA–CD44 signalling is associated with more aggressive melanoma phenotypes [17,18,19,20,21,22].